不同方案的曲妥珠单抗辅助治疗在her2阳性乳腺癌患者中的疗效和安全性:来自印度南部三级癌症中心的真实世界经验

IF 0.8 Q4 ONCOLOGY
South Asian Journal of Cancer Pub Date : 2024-11-06 eCollection Date: 2025-01-01 DOI:10.1055/s-0044-1791969
Nandini Devi Rajan, Abhilash Menon, Praveen Kumar Shenoy, Manuprasad Avaronnan, Sherin Shahana, Bindu Therayangalath
{"title":"不同方案的曲妥珠单抗辅助治疗在her2阳性乳腺癌患者中的疗效和安全性:来自印度南部三级癌症中心的真实世界经验","authors":"Nandini Devi Rajan, Abhilash Menon, Praveen Kumar Shenoy, Manuprasad Avaronnan, Sherin Shahana, Bindu Therayangalath","doi":"10.1055/s-0044-1791969","DOIUrl":null,"url":null,"abstract":"<p><p>One year of adjuvant trastuzumab is the standard of care for HER2-positive breast cancer. In low-middle income countries, delivery of 1-year trastuzumab is challenging due to significant financial burden. Evidence for shorter durations of adjuvant trastuzumab is gaining popularity in this regard. In this study, we compared the effectiveness and safety of 1 year versus shorter durations of adjuvant trastuzumab practiced in our center. In total, 312 patients were included in this analysis. The median age was 52 years. More than two-thirds of patients (67.6%) had stage 2 disease and majority were hormone-receptor-positive (62.5%). The median follow-up duration was 50 months. The 4-year disease-free survival was 97.3%. The 4-year disease-free survival for shorter durations of adjuvant trastuzumab was 98% compared with 96.7% in 1-year trastuzumab therapy group. In univariate analysis, stage at diagnosis was the only factor which had statistically significant association with disease-free survival. In multivariate analysis, none of the variables were found to be predictive of survival. Two patients (0.6%) had significant left ventricular ejection fraction decline. Shorter durations of adjuvant trastuzumab have comparable 4-year disease-free survival to standard 1-year therapy and is an alternative adjuvant treatment option for HER2-positive breast cancer patients in resource-limited settings.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"14 1","pages":"62-66"},"PeriodicalIF":0.8000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925619/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Safety Profile of Different Schedules of Adjuvant Trastuzumab Therapy among Patients with HER2-Positive Breast Cancer: Real-World Experience from a Tertiary Cancer Center in South India.\",\"authors\":\"Nandini Devi Rajan, Abhilash Menon, Praveen Kumar Shenoy, Manuprasad Avaronnan, Sherin Shahana, Bindu Therayangalath\",\"doi\":\"10.1055/s-0044-1791969\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>One year of adjuvant trastuzumab is the standard of care for HER2-positive breast cancer. In low-middle income countries, delivery of 1-year trastuzumab is challenging due to significant financial burden. Evidence for shorter durations of adjuvant trastuzumab is gaining popularity in this regard. In this study, we compared the effectiveness and safety of 1 year versus shorter durations of adjuvant trastuzumab practiced in our center. In total, 312 patients were included in this analysis. The median age was 52 years. More than two-thirds of patients (67.6%) had stage 2 disease and majority were hormone-receptor-positive (62.5%). The median follow-up duration was 50 months. The 4-year disease-free survival was 97.3%. The 4-year disease-free survival for shorter durations of adjuvant trastuzumab was 98% compared with 96.7% in 1-year trastuzumab therapy group. In univariate analysis, stage at diagnosis was the only factor which had statistically significant association with disease-free survival. In multivariate analysis, none of the variables were found to be predictive of survival. Two patients (0.6%) had significant left ventricular ejection fraction decline. Shorter durations of adjuvant trastuzumab have comparable 4-year disease-free survival to standard 1-year therapy and is an alternative adjuvant treatment option for HER2-positive breast cancer patients in resource-limited settings.</p>\",\"PeriodicalId\":22053,\"journal\":{\"name\":\"South Asian Journal of Cancer\",\"volume\":\"14 1\",\"pages\":\"62-66\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2024-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925619/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"South Asian Journal of Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/s-0044-1791969\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"South Asian Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0044-1791969","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

一年的辅助曲妥珠单抗治疗是her2阳性乳腺癌的标准治疗。在中低收入国家,由于巨大的经济负担,1年曲妥珠单抗的交付具有挑战性。在这方面,缩短辅助曲妥珠单抗持续时间的证据越来越受欢迎。在这项研究中,我们比较了1年的有效性和安全性与我们中心使用的较短时间的辅助曲妥珠单抗。共纳入312例患者。平均年龄为52岁。超过三分之二的患者(67.6%)为2期疾病,大多数为激素受体阳性(62.5%)。中位随访时间为50个月。4年无病生存率为97.3%。短时间曲妥珠单抗辅助治疗组的4年无病生存率为98%,而1年曲妥珠单抗治疗组的4年无病生存率为96.7%。在单变量分析中,诊断阶段是唯一与无病生存有统计学意义相关的因素。在多变量分析中,没有发现任何变量可以预测生存率。2例患者(0.6%)左室射血分数明显下降。辅助曲妥珠单抗的持续时间较短,与标准的1年治疗相比,4年无病生存期相当,是资源有限环境中her2阳性乳腺癌患者的替代辅助治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Efficacy and Safety Profile of Different Schedules of Adjuvant Trastuzumab Therapy among Patients with HER2-Positive Breast Cancer: Real-World Experience from a Tertiary Cancer Center in South India.

Efficacy and Safety Profile of Different Schedules of Adjuvant Trastuzumab Therapy among Patients with HER2-Positive Breast Cancer: Real-World Experience from a Tertiary Cancer Center in South India.

Efficacy and Safety Profile of Different Schedules of Adjuvant Trastuzumab Therapy among Patients with HER2-Positive Breast Cancer: Real-World Experience from a Tertiary Cancer Center in South India.

One year of adjuvant trastuzumab is the standard of care for HER2-positive breast cancer. In low-middle income countries, delivery of 1-year trastuzumab is challenging due to significant financial burden. Evidence for shorter durations of adjuvant trastuzumab is gaining popularity in this regard. In this study, we compared the effectiveness and safety of 1 year versus shorter durations of adjuvant trastuzumab practiced in our center. In total, 312 patients were included in this analysis. The median age was 52 years. More than two-thirds of patients (67.6%) had stage 2 disease and majority were hormone-receptor-positive (62.5%). The median follow-up duration was 50 months. The 4-year disease-free survival was 97.3%. The 4-year disease-free survival for shorter durations of adjuvant trastuzumab was 98% compared with 96.7% in 1-year trastuzumab therapy group. In univariate analysis, stage at diagnosis was the only factor which had statistically significant association with disease-free survival. In multivariate analysis, none of the variables were found to be predictive of survival. Two patients (0.6%) had significant left ventricular ejection fraction decline. Shorter durations of adjuvant trastuzumab have comparable 4-year disease-free survival to standard 1-year therapy and is an alternative adjuvant treatment option for HER2-positive breast cancer patients in resource-limited settings.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
80
审稿时长
35 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信